Physician profile
Todd L Teigeler
NPI 1982016614
$69,509.18
in general payments reported to CMS, 2019-2025
23 companies · $3,075 in 2025
The $3,075 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,499 · 2020: $47K · 2021: $2,693 · 2022: $8,720 · 2023: $1,296 · 2024: $4,074 · 2025: $3,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,640 · Travel and Lodging: $3,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,640.13 |
| Travel and Lodging | $3,805.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $28,672.86 | 2019-2020 | |
| Boston Scientific Corporation | $16,670.48 | 2020-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System, Farapulse |
| Biotronik INC. | $9,669.32 | 2020-2022 | |
| Abbott Laboratories | $8,607.78 | 2019-2025 | Aveir, Ensite, Tacticath Ablation Catheter, Sensor Enabled |
| Medtronic, INC. | $4,219.52 | 2021-2025 | Pulseselect, Micra, Cobalt Dr Mri Surescan |
| Biosense Webster, INC. | $558.78 | 2021-2025 | Carto 3, Nuvision Ice Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.81 | 2022-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $216.16 | 2023-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $132.84 | 2023-2024 | Camzyos |
| Novartis Pharmaceuticals Corporation | $79.39 | 2023-2025 | |
| Pfizer INC. | $68.08 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $58.00 | 2023-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $43.85 | 2025 | |
| Impulse Dynamics (USA) INC. | $43.06 | 2023 | Optimizer |
| Amgen INC. | $42.83 | 2022-2023 | Repatha |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $41.86 | 2019-2024 | Farxiga |
| Bridgebio Pharma, INC. | $32.80 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $31.29 | 2025 | Assure Wcd |
| Cardiva Medical, INC. | $29.24 | 2024 | Optowire |
| Terumo Medical Corporation | $20.04 | 2024 | Metacross Otw, Glidewire |
| Acutus Medical, INC. | $19.79 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.42 | 2023 | |
| Alnylam Pharmaceuticals INC. | $13.98 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Teigeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.